A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies

Study Purpose:

The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

Study Status:

Not recruiting

Disease:

Alzheimer's Disease , Multiple Sclerosis , Parkinson's Disease , Huntington's Disease , Amyotrophic Lateral Sclerosis (ALS)

Study Type:

Observational

Type of Intervention:

N/A

Intervention Name:

N/A

Placebo:

N/A

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Phil Silkoff, MD, Sanguine Biosciences

Clinicaltrials.gov ID:

NCT01592552

Neals Affiliated?

No

Coordinating Center Contact Information

Sanguine Biosciences

Los Angeles, California, 91403 United States

Full Study Summary:

Blood samples are collected in the comfort and safety of your home by a certified medical professional. We have mobile phlebotomists located in major metropolitan areas around the nation for your convenience.

Study Sponsor:

Sanguine Biosciences

Estimated Enrollment:

20

Estimated Study Start Date:

10 / 31 / 2011

Estimated Study Completion Date:

03 / 01 / 2015

Posting Last Modified Date:

04 / 08 / 2019

Date Study Added to neals.org:

05 / 07 / 2012

Alternative Study Name: A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

https://clinicalt...CT01592552&rank=1

Minimum Age:

18 Years

Maximum Age:

100 Years

Inclusion Criteria:

- Males and females >18 to 100 years old

- A diagnosis of neurological condition

- Proof of diagnosis can be provided

Control group: Healthy donors, males and females, 18 to 100 years of age

Exclusion Criteria

- Receipt of blood products within 30 days of study enrollment

- Receipt of an investigational (unapproved) drug within 30 days of study enrollment

Sanguine Biosciences

Sherman Oaks, California 91403
United States